Last10K.com

Bellerophon Therapeutics, Inc. (BLPH) SEC Filing 8-K Material Event for the period ending Wednesday, January 5, 2022

Bellerophon Therapeutics, Inc.

HISTORY TOOLS
CIK: 1600132 Ticker: BLPH

View differences made from one to another to evaluate Bellerophon Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bellerophon Therapeutics, Inc..

Continue

Assess how Bellerophon Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information

Material Contracts, Statements, Certifications & more

Bellerophon Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: BLPH
CIK: 1600132
Form Type: 8-K Corporate News
Accession Number: 0001558370-22-000053
Submitted to the SEC: Wed Jan 05 2022 8:39:33 AM EST
Accepted by the SEC: Wed Jan 05 2022
Period: Wednesday, January 5, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/blph/0001558370-22-000053.htm